BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 18, 2012
View Archived Issues
Taisho Pharmaceutical announces new GlyT1 inhibitors
Read More
New Exp1 inhibitors show promise in a number of in vitro and in vivo cancer studies
Read More
Morphotek evaluates MORAb-004 in new phase II trial
Read More
BioAlliance plans phase II Clonidine Lauriad study expansion
Read More
FDA requests more information for HyQ BLA
Read More
PRINT nanofabrication allows precision synthesis of therapeutic particles
Read More
Merck & Co. selects lead from new series of phosphodiesterase 10A inhibitors
Read More
Sanofi presents novel oncolytic drug candidate
Read More
Preclinical results demonstrate significant early antitumor efficacy of new immunotherapy
Read More
Johnson & Johnson reviews progress of first quarter 2012
Read More
DFH Pharma and NIH collaborate on development of HIV drugs
Read More
Abbott in-licenses Stanford University biomarkers for prostate cancer
Read More
Dyax and Eclipse Therapeutics enter licensing agreement
Read More
Highly potent and selective EZH2 inhibitors discovered by GSK
Read More
Depomed plans NDA filing for Serada
Read More
Novel ERK inhibitors designed
Read More
Novel PI3Kalpha/mTOR inhibitors developed at Hutchison MediPharma
Read More
Exelixis scientists discover new JAK1 inhibitors
Read More
New lysophospholipid S1P1 receptor agonists patented
Read More
Treatment begins in phase II IMO-3100 trial
Read More
Melanoma trial of SCIB-1 clear to advance to phase II
Read More
Intellect Neurosciences collaborates with leading Alzheimer's research group
Read More
AMRI enters into development and manufacturing deal
Read More
ImmunoGen reports advances in its anticancer drug pipeline
Read More
GE Healthcare enters Alzheimer's disease collaboration
Read More
Confirmatory data support efficacy of Phytopharm ALS candidate drug
Read More